Literature DB >> 12874035

Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression.

Graham P Pidgeon1, Keqin Tang, Yin Long Cai, Evano Piasentin, Kenneth V Honn.   

Abstract

Arachidonic acid metabolism leads to the generation of biologically active metabolites that regulate cell growth and proliferation, as well as survival and apoptosis. We have demonstrated previously that platelet-type 12-lipoxygenase (LOX) regulates the growth and survival of a number of cancer cells. In this study, we show that overexpression of platelet-type 12-LOX in prostate cancer PC3 cells or epithelial cancer A431 cells significantly extended their survival and delayed apoptosis when cultured under serum-free conditions. These effects were shown to be a result of enhanced surface integrin expression, resulting in a more spread morphology of the cells in culture. PC3 cells transfected with 12-LOX displayed increased alpha(v)beta(3) and alpha(v)beta(5) integrin expression, whereas other integrins were unaltered. Transfected A431 cells did not express alpha(v)beta(3); however, alpha(v)beta(5) integrin expression was increased. Treatment of both transfected cell lines with monoclonal antibody to alpha(v)beta(5) (and in the case of PC3 cells, anti-alpha(v)beta(3)) resulted in significant apoptosis. In addition, treatment with 100 nM 12(S)-hydroxy-eicosatetraenoic acid, the end product of platelet-type 12-LOX, but not other hydroxy-eicosatetraenoic acids, enhanced the survival of wild-type PC3 and A431 cells and resulted in increased expression of alpha(v)beta(5). Furthermore, Baicalein or N-benzyl-N-hydroxy-5-phenylpentamide, specific 12-LOX inhibitors, significantly decreased alpha(v)beta(5)-mediated adhesion and survival in 12-LOX-overexpressing cells. The results show that 12-LOX regulates cell survival and apoptosis by affecting the expression and localization of the vitronectin receptors, alpha(v)beta(3) and alpha(v)beta(5), in two cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874035

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors:  Deborah A Bradley; Stephanie Daignault; Charles J Ryan; Robert S Dipaola; Kathleen A Cooney; David C Smith; Eric Small; Paul Mathew; Mitchell E Gross; Mark N Stein; Alice Chen; Kenneth J Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T Keller; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-03-25       Impact factor: 3.850

Review 2.  Molecular determinants of P2Y2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes.

Authors:  Gary A Weisman; M Wang; Q Kong; N E Chorna; J T Neary; Grace Y Sun; Fernando A González; C I Seye; L Erb
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 3.  Targeted approaches for the management of metastatic prostate cancer.

Authors:  Kathleen W Beekman; Maha Hussain
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

Review 4.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells.

Authors:  Bo Yin; Yang Yang; Zhiqiang Zhao; Yu Zeng; Steven M Mooney; Ming Li; Xuewen Xu; Yongsheng Song; Bin Wu; Zhibo Yang
Journal:  Int J Oncol       Date:  2011-01-11       Impact factor: 5.650

6.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

7.  Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.

Authors:  Yunpeng Ye; Sharon Bloch; Baogang Xu; Samuel Achilefu
Journal:  J Med Chem       Date:  2006-04-06       Impact factor: 7.446

8.  Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid.

Authors:  Yande Guo; Wenliang Zhang; Craig Giroux; Yinlong Cai; Prasanna Ekambaram; Ashok-Kumar Dilly; Andrew Hsu; Senlin Zhou; Krishna Rao Maddipati; Jingjing Liu; Sangeeta Joshi; Stephanie C Tucker; Menq-Jer Lee; Kenneth V Honn
Journal:  J Biol Chem       Date:  2011-06-28       Impact factor: 5.157

Review 9.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.

Authors:  William S Powell; Joshua Rokach
Journal:  Biochim Biophys Acta       Date:  2014-10-29

Review 10.  Mammalian lipoxygenases and their biological relevance.

Authors:  Hartmut Kuhn; Swathi Banthiya; Klaus van Leyen
Journal:  Biochim Biophys Acta       Date:  2014-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.